VitriVax Inc.

A formulation technology company engineering innovative solutions to maximize global accessibility and utility of human vaccines—vaccines that save lives and protect our world from preventable disease.

The University of Colorado Connection

VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of (ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Molecular, Cellular & Developmental Biology) and Ìý(ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Chemical and Biological Engineering).

Funding Status and Investment Opportunities

  • Industry Applications: Health and Wellness, Biotech​, Manufacturing​, Therapeutics, Vaccines
  • Funding Stage: Series B Round or beyond
  • Contact for Investment Inquiries: Rom Colindres, CEO, rcolindres@vitrivaxbio.com

In the News

More Startups News

Venture Partners Programs​

Path to Commercialization

Development Funding

Gates Foundation

Gates Foundation

ÌýÌý ÌýThis page was last updated on April 14, 2025. Please email vpnews@colorado.edu for corrections or updates

The InsiderÌýisÌýVenture Partners at ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ's monthly newsletter featuring theÌýlatest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences.

Subscribe to The InsiderÌýÌý

Questions about investment opportunities?

Amy Dodenhoff

Amy Dodenhoff · Director of Venture Development

Contact AmyÌý

Media Inquiries

For marketing inquiries and news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ.

For media inquiries, please visit .